June #82 : Tat's Two - by Mike Barr

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Kiss & Gel

Odd Boy Out

Pain Killer Pain

Gravest Show on Earth

Enemy at the Gate

How to Parent

On the High Wire

Party Politics

PACHA Gotcha

Waste Product

Three Wise Men

Poppy Culture

State of Race

Jail Tail

Ohio File

Oh! Calcutta!

School for Scandal

B Sting

Stat Splat

Beg To Differ

Oh, God!

Laughing Matters

Cable Ace

Bullox over Broadway

A Pair of Genes

Gene Machine

An STI FYI

Fly by Night

All the News That's Fit to Zip...

Classical Lit

The Pill Chill

Mixed Signals

Tat's Two

Gender Bender

Whodunit

Who's Who

Big Sis

Clean Screen

Obituary

Obits

Asimov As He Was

Milestones

Tricks of the Trade

Cunning Linguist

Editor's Letter

Mailbox

Bloodless, Still Gutsy



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

June 2002

Tat's Two

by Mike Barr

For years the idea of a therapeutic vaccine for people with HIV was little more than a pipe dream, but as of 2002 there are two in the pipeline ready for human tests. Top-billed is a Merck star that targets gag, a protein once thought to be HIV's Achilles' heel and still viewed as a key to cellular immune response (see "Prime Time," POZ, May 2002). A featured player in the vax drama is the tat-based product -- tat is a protein that serves as the on-and-off switch for HIV replication -- being developed by Robert Gallo, MD, in conjunction with longtime collaborator Daniel Zagury, MD, of Paris' Institut Pasteur.

In contrast to the Merck gag-based vax, Gallo's tat evolved into a vaccine for the already-infected apparently by default -- it simply didn't fare well in preventive studies. The tat protein has long been considered a logical target because it is expressed early in HIV's life cycle, so disabling it might be an efficient way to block the virus' development. But even when the vaccine boosted immune responses to HIV, it was a bust as an infection fighter.

The human tests will run for five months, with 32 HIVers with undetectable viral loads getting tat in a series of jabs. They will remain on HAART during the trial, which is primarily designed to establish the vaccine's safety and ability to stimulate an appropriate immune response.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    acousticmat
    Tucson
    Arizona


    romanticseattle
    Tacoma
    Washington


    max38man
    Chicago
    Illinois


    kmfdm221
    Arcata
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been tested for hepatitis C?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.